Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Min Kyong Moon"'
Publikováno v:
Diabetes & Metabolism Journal
BACKGROUND The study aimed to evaluate the effects of dapagliflozin and metformin on vascular endothelial function and renal injury markers. METHODS This prospective, randomized, open-label, crossover study included drug-naive patients with type 2 di
Autor:
Min Kyong Moon, Kun Ho Yoon, Young Hye You, Seung Hyun Ko, Ji-Won Kim, Ye Jee Lee, Yu Bae Ahn
Publikováno v:
Journal of Cellular Biochemistry. 120:8534-8546
Objective We investigated the effects of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes (T2DM). Methods Empagliflozin (OLETF-EMPA) or voglib
Autor:
Moon-Kyu Lee, Mi-Kyung Kim, Eun Sook Kim, Gyuri Kim, Soo Lim, Kyu Jeung Ahn, Hye Soon Kim, Ie Byung Park, Sin Gon Kim, Min Kyong Moon, Chang Beom Lee, Tae Ho Kim, Seok Won Park, Hyuk-Sang Kwon, Kang Seo Park, Su Kyoung Kwon, Choon Hee Chung, Dong Jin Chung, Cheol-Young Park
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To investigate the efficacy and safety of evogliptin compared with linagliptin in patients with type 2 diabetes. Materials and Methods In this 12‐week, multicentre, randomized, double‐blind, active‐controlled, and 12‐week open‐label ext
Autor:
Kyu Yeon Hur, Kyung Mook Choi, Jin Hwa Kim, Sang Youl Rhee, Min Kyong Moon, Seok O Park, Byung Wan Lee, Hyun-Jin Kim, Seung Hyun Ko, Nan Hee Kim
Publikováno v:
The Korean Journal of Internal Medicine
Diabetes & Metabolism Journal, Vol 41, Iss 5, Pp 349-356 (2017)
Diabetes & Metabolism Journal
Diabetes & Metabolism Journal, Vol 41, Iss 5, Pp 349-356 (2017)
Diabetes & Metabolism Journal
In order to improve the quality of life and to prevent chronic complications re lated to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When u
Publikováno v:
Diabetes & Metabolism Journal, Vol 41, Iss 1, Pp 23-30 (2017)
Diabetes & Metabolism Journal
Europe PubMed Central
Diabetes & Metabolism Journal
Europe PubMed Central
Background There has been evidences of ethnic differences in the low density lipoprotein cholesterol (LDL-C) lowering effect of statin. We aimed to evaluate the efficacy of moderate-intensity statins in the treatment of dyslipidemia among Korean pati
Autor:
Sam Kwon, Min Kyong Moon, Kun-Ho Yoon, Soo Lim, Eun Sook Kim, Eun Young Kim, Sung-Ho Kim, Kyung Ah Han, Mi-Kyung Kim, Jaemyung Yu, Dong-Jun Kim, Kwan Woo Lee, Moon-Kyu Lee, Manaj Wongtanate, Parinya Chamnan
Publikováno v:
Diabetes, Obesity & Metabolism
Background Gemigliptin is a new dipeptidyl peptidase-IV inhibitor. We investigated the efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes (T2D)
Autor:
Choon H. Chung, Hyuk-Sang Kwon, Kang Seo Park, Sin Gon Kim, Eunsook Kim, Tae Ho Kim, Soo Lim, Cheol-Young Park, Hye Soon Kim, Su Kyoung Kwon, Ie Byung Park, Kyu Chang Won, Moon-Kyu Lee, Kyu Jeung Ahn, Mi-Kyung Kim, Chang Beom Lee, Min Kyong Moon, Seok Won Park, Gyuri Kim, Dong Jin Chung
Publikováno v:
Diabetes. 68
Background and Aims: Evogliptin is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. We investigated the efficacy and safety of Evogliptin compared with linagliptin in patients with type 2 diabetes (T2D). Materials and Methods: A total of 207 untreated
Autor:
Hyun Shik Son, Chul Woo Ahn, Sangmo Hong, Moon-Kyu Lee, Min Kyong Moon, Yong‐Wook Cho, Choon Hee Chung, Sung Woo Park, Cheol-Young Park, Kyung Ah Han, Chang Beom Lee, Hak Chul Jang, Bon Jeong Ku
Publikováno v:
Diabetes, Obesity & Metabolism
We assessed the 24‐week efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in Korean patients with type 2 diabetes mellitus (T2DM) that was inadequately controlled with diet and exercise. The present study was designe
Publikováno v:
Journal of clinical lipidology. 11(6)
Background Thyroid hormone regulates lipid metabolism. In particular, it has been reported to regulate plasma high-density lipoprotein cholesterol (HDL-C) levels and the activity of molecules involved in HDL metabolism. Objective We investigated chan
Publikováno v:
Diabetes & Metabolism Journal
The study aimed to evaluate the effects of dapagliflozin and metformin on vascular endothelial function and renal injury markers.This prospective, randomized, open-label, crossover study included drug-naïve patients with type 2 diabetes mellitus, wh